Albemarle Corporation to Expand Ibuprofen Capacity

Apr 20, 2001, 01:00 ET from Albemarle Corporation

    BATON ROUGE, La., April 20 /PRNewswire Interactive News Release/ --
 Albemarle Corporation (NYSE:   ALB) will expand the capacity of its Orangeburg,
 SC bulk-active ibuprofen plant by approximately 30 percent.  Capital
 expenditures are also underway to further improve ibuprofen product quality
 and consistency to create the highest quality in the world.
     Expansion of the plant, which is already the largest bulk-active ibuprofen
 facility in the world, is expected to be completed in several stages, with
 full implementation within the next 12 to 18 months.
     "This expansion reflects Albemarle's commitment to lead the ibuprofen
 market and to support the growing demand of Albemarle's ever-increasing global
 customer base," says Greg Lambeth, global business manager.
     Albemarle currently supplies bulk actives and pharmaceutical intermediates
 to over 250 customers in more than 50 countries.
     A global supplier of specialty and fine chemicals that enhance consumer
 products, Albemarle Corporation serves markets for polymers, surfactants and
 biocides, pharmaceuticals, agricultural chemicals, photographic chemicals,
 water treatment and petroleum products.  For more information on Albemarle
 visit www.albemarle.com.
 
     Albemarle Cautionary Note on Forward Looking Statements
     Some of the information contained in this release constitutes forward
 looking statements within the meaning of the Private Securities Litigation
 Reform Act of 1995.  Although Albemarle Corporation believes its expectations
 are based on reasonable assumptions within the bounds of its knowledge of its
 business and operations, there can be no assurance that actual results will
 not differ materially from its expectations.  Factors which could cause actual
 results to differ from expectations include, without limitation, the timing of
 orders received from customers, the gain or loss of significant customers,
 competition from other manufacturers, changes in demand for the Company's
 products, increases in the cost of the product, changes in the market in
 general, fluctuations in foreign currencies and significant changes in new
 product introduction resulting in an increase in capital project requests and
 approvals leading to capital spending.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X02326751
 
 

SOURCE Albemarle Corporation
    BATON ROUGE, La., April 20 /PRNewswire Interactive News Release/ --
 Albemarle Corporation (NYSE:   ALB) will expand the capacity of its Orangeburg,
 SC bulk-active ibuprofen plant by approximately 30 percent.  Capital
 expenditures are also underway to further improve ibuprofen product quality
 and consistency to create the highest quality in the world.
     Expansion of the plant, which is already the largest bulk-active ibuprofen
 facility in the world, is expected to be completed in several stages, with
 full implementation within the next 12 to 18 months.
     "This expansion reflects Albemarle's commitment to lead the ibuprofen
 market and to support the growing demand of Albemarle's ever-increasing global
 customer base," says Greg Lambeth, global business manager.
     Albemarle currently supplies bulk actives and pharmaceutical intermediates
 to over 250 customers in more than 50 countries.
     A global supplier of specialty and fine chemicals that enhance consumer
 products, Albemarle Corporation serves markets for polymers, surfactants and
 biocides, pharmaceuticals, agricultural chemicals, photographic chemicals,
 water treatment and petroleum products.  For more information on Albemarle
 visit www.albemarle.com.
 
     Albemarle Cautionary Note on Forward Looking Statements
     Some of the information contained in this release constitutes forward
 looking statements within the meaning of the Private Securities Litigation
 Reform Act of 1995.  Although Albemarle Corporation believes its expectations
 are based on reasonable assumptions within the bounds of its knowledge of its
 business and operations, there can be no assurance that actual results will
 not differ materially from its expectations.  Factors which could cause actual
 results to differ from expectations include, without limitation, the timing of
 orders received from customers, the gain or loss of significant customers,
 competition from other manufacturers, changes in demand for the Company's
 products, increases in the cost of the product, changes in the market in
 general, fluctuations in foreign currencies and significant changes in new
 product introduction resulting in an increase in capital project requests and
 approvals leading to capital spending.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X02326751
 
 SOURCE  Albemarle Corporation